Chenyu Lin, MD @ChenyuLinMD profile

Chenyu Lin, MD

@ChenyuLinMD

Followers

549

Following

2K

Statuses

525

Oncologist & Clinical Investigator @DukeCancer @VADurham | Cellular Therapy, Leukemia/Lymphoma, Digital Health | Posts ≠ med advice

Durham, NC

Joined May 2021

Don't wanna be here? Send us removal request.

Chenyu Lin, MD

@ChenyuLinMD

1 day

@7eyeblink @AnnaSureda5 For DLBCL, Liso-cel is very promising and I often use it when trying to reduce toxicity. The downside is that I’ve not yet seen TRANSFORM’s long term data to show OS benefit like with ZUMA-7.

0

1

Chenyu Lin, MD

@ChenyuLinMD

4 days

RT @DavidSteensma: When reports emerged in 2023 of T cell secondary malignancies in CAR-T treated pts, mechanism was unclear. New MSKCC re…

0

58

0

Chenyu Lin, MD

@ChenyuLinMD

4 days

Inspirational! Where do I get a copy?

Duke Hematologic Malignancies & Cellular Therapy

@DukeHMCT

4 days

ICYMI: @Cristin53875581, our @DukeCancer myeloma section lead, was the chief cyclist for the @IMFmyeloma Iceland Cycling Expedition. This dedicated group of doctors, researchers, and patients biked across Iceland to raise money and awareness for #MultipleMyeloma and #MGUS. The documentary of their journey won the Best Documentary Short at the 2024 @worldfilmcannes! #MMsm

0

4

Chenyu Lin, MD

@ChenyuLinMD

8 days

RT @MahadeoKris: Registration open. Hemophagocytic Lymphohistiocytosis (HLH) Across Pediatric Specialties: Spotlight on Immune Effector C…

0

5

0

Chenyu Lin, MD

@ChenyuLinMD

15 days

@drjgauthier It seems you’ve been living a lie

1

0

1

Chenyu Lin, MD

@ChenyuLinMD

20 days

@drjgauthier I think the takeaway is that both are reasonable and there probably isn’t a right answer. Difficult situation with post-cart relapse. I’ve seen good and bad outcomes from both approaches.

0

3

Chenyu Lin, MD

@ChenyuLinMD

25 days

RT @DrJFriedberg: The next frontier: Chimeric Antigen Receptor-T Cells in Colorectal Cancer: Pioneering New Avenues in Solid Tumor Immunoth…

0

1

0

Chenyu Lin, MD

@ChenyuLinMD

26 days

RT @KUcancercenter: A multicenter #ClinicalTrial led by researchers at the Center for Survivorship and Patient-Oriented Research at @KUcanc…

0

4

0

Chenyu Lin, MD

@ChenyuLinMD

2 months

Merry Christmas and happy holidays from the @DukeHMCT inpatient blood cancer service Christmas crew! Many thanks to the @DukeCancer staff and everyone else working this holiday week. @IMResidencyDuke

0

2

14

Chenyu Lin, MD

@ChenyuLinMD

2 months

RT @dukemedicine: Kudos to Dr. Katherine Zhou (PGY-5, Hematology & Oncology) for her exceptional care! A veteran's son recently honored her…

0

2

0

Chenyu Lin, MD

@ChenyuLinMD

2 months

First MSC approval by @FDAOncology for steroid-refractory acute #GVHD in pediatric patients! Fascinating and promising technology for an area of significant unmet need. #Remestemcel #Ryoncil $MESO

0

3

13

Chenyu Lin, MD

@ChenyuLinMD

2 months

RT @ASCO: #Telehealth flexibilities expire soon. Without legislation, pre-COVID restrictions requiring pts live in a designated area & go t…

0

20

0

Chenyu Lin, MD

@ChenyuLinMD

2 months

RT @calliecoombsmd: WOW- practice changing MCL trial showing no benefit of autoHCT in uMRD MCL in first remission. Bravo ECOG team. @timfen…

0

29

0

Chenyu Lin, MD

@ChenyuLinMD

2 months

RT @VincentRK: Just out: Paradigm changing AQUILA randomized trial in high risk smoldering myeloma #ASH24 @thanosdimop @NEJM Daratumumab…

0

127

0

Chenyu Lin, MD

@ChenyuLinMD

2 months

Thanks to the #ASH24 organizers for a great meeting and the chance to reconnect with old friends & collaborators! Grateful for the opportunity to co-chair the ALL/lymphoma CAR-T session with @theNCI Dr. #KathrynCappell. See you all in ☀️ FL for #ASH25! @ASH_hematology @DukeCancer

1

2

18

Chenyu Lin, MD

@ChenyuLinMD

2 months

RT @TalhaBadarMD: #ASH24 Another very productive #ASH for COMMAND consortium. Presenting several abstracts on acute leukemia and myeloid di…

0

6

0